Theralase Technologies Inc (fka TLT.V)

[pointofreturn]

Biotechnology Focus, Scientific Paper Reports

Two of the top scientic researchers from Princess Margaret Cancer Centre, University Health Network both are working with Theralase Dr. Lothar Lilge, senior scientist and Dr. Michael Jewett, clinical principal scientific investigator are looking forward to phase 1/2 clinical trials coming up.

Scientific paper reports Theralase compounds destroy bacteria in low oxygen environments

theralaseUnique characteristics of new photo dynamic compounds has application in destruction of lung, breast, brain, bladder and prostate cancers

Theralase Technologies Inc. reports that a recently published scientific paper indicates that its new family of Photo Dynamic Compounds (PDCs) are able to destroy two types of bacteria (Staphylococcus aureus (s. aureus) and Methicillin Resistant Staphylococcus aureus (MRSA)) in low oxygen atmospheres.

The results are considered pivotal because they validate Theralase PDCs efficacy in both normal and low oxygen environments and shows that they are able to be used in both bacteria and cancer destruction. According to Dr. Arkady Mandel, chief scientific officer of Theralase Inc., the technology could offer a new paradigm for destruction of low oxygenated cancerous tumours because of its ability to be effective in low oxygen environments, specifically against non-muscle invasive bladder cancer.

“This form of disease represents up to 75 per cent of newly diagnosed bladder cancer cases accounting for more than 386,000 cases and 150,000 deaths annually worldwide. The abnormal decrease or the lack of oxygen supply to cells and tissues is called hypoxia and commonly presents in solid cancers, such as brain, bladder, breast, lung and prostate. Hypoxic cancers are extremely aggressive, resistant to standard therapies (chemotherapy and radiotherapy), and thus very difficult to destroy. Tumour hypoxia is known to play a role in cancer metastasis (spread) and resistance to therapy, as well as the ability of cancer cells to escape destruction by the immune system.”

According to Dr. Mandel, the evidence supporting the Theralase PDC technology represents a potential solution for such hypoxic cancers.

Dr. Lothar Lilge, senior scientist at the Princess Margaret Cancer Centre, University Health Network further comments that, “In well oxygenated environments, these new PDCs generate singlet oxygen, a dominant cytotoxic substance with close to 100 per cent efficacy, yet under hypoxia (low oxygen) conditions, they display the remarkable ability to switch to a Type 1 or oxygen independent cytotoxic substance owing to their ability to simultaneously act as an excited state oxidant and reductant. The intrinsic positive charge of the Ru(II) metal combined with the oxygen independent light activated cytotoxicity demonstrated by this family of PDCs opens a new strategy for destroying both gram-positive and gram-negative bacteria regardless of oxygenation level. Therefore, this has a significant impact on the destruction of cancer cells by PDC technology, as a considerable fraction of cancer will survive in low oxygen environments and according to the literature this is one of the causes for recurrence of cancer post therapy.”

http://biotechnologyfocus.ca/scientific-paper-reports-theralase-compounds-destroy-bacteria-in-low-oxygen-environments/

Read more at http://www.stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc#ly1qcrPkjZ5Br4eZ.99